Please use this identifier to cite or link to this item:
|Title:||Structure-activity analysis of 2′-modified cinnamaldehyde analogues as potential anticancer agents||Authors:||Gan, F.F.
|Issue Date:||2-Oct-2009||Citation:||Gan, F.F., Chua, Y.S., Scarmagnani, S., Palaniappan, P., Franks, M., Poobalasingam, T., Bradshaw, T.D., Westwell, A.D., Hagen, T. (2009-10-02). Structure-activity analysis of 2′-modified cinnamaldehyde analogues as potential anticancer agents. Biochemical and Biophysical Research Communications 387 (4) : 741-747. ScholarBank@NUS Repository. https://doi.org/10.1016/j.bbrc.2009.07.104||Abstract:||The natural product 2′-hydroxycinnamaldehyde (HCA) and its analogue, 2′-benzoyloxycinnamaldehyde (BCA), have been previously shown to have antiproliferative and proapoptotic effects in vitro and inhibit tumor growth in vivo. In this study, we use structure-activity analysis to define structural features that are important for the activity of cinnamaldehyde analogues. Our results emphasize an important role for both the propenal group as well as the modification at the 2′-position. Further studies were aimed to characterize the mechanism of action of BCA. Exposure to BCA induced cell death via caspase-dependent and -independent pathways. Cell death was not due to autophagy or necrosis as a result of energy depletion or induction of reactive oxygen species. Our findings have important implications for future drug design and highlight the importance of defining molecular drug targets for this promising class of potential anticancer agents. © 2009 Elsevier Inc. All rights reserved.||Source Title:||Biochemical and Biophysical Research Communications||URI:||http://scholarbank.nus.edu.sg/handle/10635/106368||ISSN:||0006291X||DOI:||10.1016/j.bbrc.2009.07.104|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Sep 30, 2020
WEB OF SCIENCETM
checked on Sep 23, 2020
checked on Sep 26, 2020
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.